Express News | Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Moomoo 24/7Apr 24 16:01 ET
Karyopharm Therapeutics (KPTI) Gets a Buy From Piper Sandler
TipRanksApr 22 08:33 ET
Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor
Onco360, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO (selinexor), a first-in-class, XPO-1 inhibitor. XPOV
BenzingaMar 13 16:38 ET
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Seeking AlphaMar 10 13:08 ET
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
PRNewswireMar 6 16:05 ET
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
TipRanksMar 5 03:20 ET
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
Yahoo FinanceMar 4 23:53 ET
Barclays Gives a Buy Rating to Karyopharm Therapeutics (KPTI)
TipRanksMar 4 02:55 ET
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported And Analysts Have Been Cutting Their Estimates
Last week, you might have seen that Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its yearly result to the market. The early response was not positive, with shares down 4.4% to US$1.19 in the pa
Simply Wall StMar 3 08:50 ET
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanksMar 1 07:28 ET
Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 1 07:20 ET
Express News | HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8
Moomoo 24/7Mar 1 07:10 ET
Karyopharm Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/01/2024 595.65% HC Wainwright & Co. $10 → $8 Maintains Buy 11/03/2023 334.78% Piper Sandler $7 → $5 Mai
BenzingaMar 1 07:09 ET
Bad News for Karyopharm Therapeutics INC Stock: This New Risk Has Been Added
TipRanksMar 1 01:02 ET
Earnings Call Summary | Karyopharm Therapeutics(KPTI.US) Q4 2023 Earnings Conference
The following is a summary of the Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript:Financial Performance:Karyopharm Therapeutics reported $112 million XPOVIO net revenue for 2023,
moomoo AIFeb 29 13:58 ET · Conference Call
Karyopharm Therapeutics Sees 2024 U.S. Xpovio Net Product Revenue $100M-$120M >KPTI
Karyopharm Therapeutics Sees 2024 U.S. Xpovio Net Product Revenue $100M-$120M >KPTI
Dow JonesFeb 29 07:35 ET
Express News | Karyopharm Sees 2024 Total Revenue $140M-$160M Vs $152.02M Est
Moomoo 24/7Feb 29 07:31 ET
Express News | Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
Moomoo 24/7Feb 29 07:31 ET
Karyopharm Therapeutics 4Q Loss $41.8M >KPTI
Karyopharm Therapeutics 4Q Loss $41.8M >KPTI
Dow JonesFeb 29 07:30 ET
Karyopharm Therapeutics 4Q Loss/Shr 36c >KPTI
Karyopharm Therapeutics 4Q Loss/Shr 36c >KPTI
Dow JonesFeb 29 07:30 ET
No Data
No Data